Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
TREM2 is a receptor for lipids expressed in microglia. The R47H variant of human TREM2 impairs ligand binding and increases Alzheimer’s disease (AD) risk. In mouse models of amyloid β (Aβ) accumulation, defective TREM2 function affects microglial response to Aβ plaques, exacerbating tissue damage, whereas TREM2 overexpression attenuates pathology. Thus, AD may benefit from TREM2 activation. Here, we examined the impact of an anti-human TREM2 agonistic mAb, AL002c, in a mouse AD model expressing either the common variant (CV) or the R47H variant of TREM2. Single-cell RNA-seq of microglia after acute systemic administration of AL002c showed induction of proliferation in both CV- and R47H-transgenic mice. Prolonged administration of AL002c reduced filamentous plaques and neurite dystrophy, impacted behavior, and tempered microglial inflammatory response. We further showed that a variant of AL002c is safe and well tolerated in a first-in-human phase I clinical trial and engages TREM2 based on cerebrospinal fluid biomarkers. We conclude that AL002 is a promising candidate for AD therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures














Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AL002 (27) is a TREM2-specific monoclonal antibody that activates TREM2 to enhance microglial function, thereby reducing Aβ plaque formation and attenuating neurite dystrophy.474”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [474]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“enhancing TREM2 signaling by TREM2 agonist antibody, direct delivery of the TREM2 gene, or stimulating other pathways to increase TREM2 expression in the brains of AD mice enhanced Aβ phagocytosis and improved cognitive behaviors.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence has shown that TREM2 activation increased Aβ phagocytosis, relieved neuroinflammation, and improved cognitive behavior in AD mouse models.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In an AD mouse model, administration of AL002c, a variant of the AL002 antibody, attenuated tau plaques and neurite dystrophy, improved behavior, and reduced microglial inflammation.537”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [537]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The opposite phenotypes observed in PLCG2 KO iMGs and Plcγ2-P522R KI mice also support the notion to therapeutically stimulate TREM2 functions [6, 16, 17, 43].”
From The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions (2020) · cites this paper as [17]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo
Nimmerjahn, A., Kirchhoff, F., & Helmchen, F. (2005) · Science · doi:10.1126/science.1110647 · Cited by 5,827
A Unique Microglia Type Associated with Restricting Development of Alzheimer’s Disease
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., Ulland, T. K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.018 · Cited by 5,493
Self-citationDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 1×
“In this model, plaques become clearly detectable at 3–4 mo of age and continue to grow for several months (Oakley et al., 2006).”
MethodAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Single-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
Cited by
Items 101–200 of 579
Microglia Heterogeneity in Alzheimer’s Disease: Insights From Single-Cell Technologies
Wang, H. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.773590 · Cited by 70
Qiu, Y., Shen, X., Ravid, O., Atrakchi, D., Rand, D., Wight, A. E., Kim, H.-J., Liraz-Zaltsman, S., Cooper, I., Schnaider Beeri, M., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218915120 · Cited by 61
Regulation of microglia population dynamics throughout development, health, and disease
Hammond, B. P., Manek, R., Kerr, B. J., Macauley, M. S., & Plemel, J. R. (2021) · Glia · doi:10.1002/glia.24047 · Cited by 65
Jairaman, A., McQuade, A., Granzotto, A., Kang, Y. J., Chadarevian, J. P., Gandhi, S., Parker, I., Smith, I., Cho, H., Sensi, S. L., et al. (2022) · eLife · doi:10.7554/elife.73021 · Cited by 61
Secretases in Alzheimer's disease: Novel insights into proteolysis of APP and TREM2
Lichtenthaler, S. F., Tschirner, S. K., & Steiner, H. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2021.09.003 · Cited by 60
Dhandapani, R., Neri, M., Bernhard, M., Brzak, I., Schweizer, T., Rudin, S., Joller, S., Berth, R., Kernen, J., Neuhaus, A., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110883 · Cited by 60
Alzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response
Wang, Z., Zhang, L., & Qin, C. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00857-6 · Cited by 65
Disease-associated microglia in neurodegenerative diseases: Friend or foe?
Cheng, Y.-H., & Ho, M. S.-C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003426 · Cited by 65
TREM2 Promotes Immune Evasion by Mycobacterium tuberculosis in Human Macrophages
Dabla, A., Liang, Y. C., Rajabalee, N., Irwin, C. L., Moonen, C. G. J., Willis, J. V., Berton, S., & Sun, J. (2022) · mBio · doi:10.1128/mbio.01456-22 · Cited by 62
Missiego-Beltrán, J., & Beltrán-Velasco, A. I. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810041 · Cited by 60
Boddupalli, C. S., Nair, S., Belinsky, G. S., Gans, J., Teeple, E. A., Nguyen, T., Mehta, S. S., Guo, L., Kramer, M. L., Ruan, J., et al. (2022) · eLife · doi:10.7554/elife.79830 · Cited by 57
Omics-based biomarkers discovery for Alzheimer's disease
Aerqin, Q., Wang, Z.-T., Wu, K., He, X., Dong, Q., & Yu, J. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04614-6 · Cited by 59
Chen, Y., Kou, Y., Ni, Y., Yang, H., Xu, C., Fan, H., & Liu, H. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03428-0 · Cited by 62
Aducanumab anti-amyloid immunotherapy induces sustained microglial and immune alterations
Cadiz, M. P., Gibson, K. A., Todd, K. T., Nascari, D. G., Massa, N., Lilley, M. T., Olney, K. C., Al-Amin, M. M., Jiang, H., Holtzman, D. M., et al. (2024) · Journal of Experimental Medicine · doi:10.1084/jem.20231363 · Cited by 55
“…including amyloidosis, tauopathy, and amyotrophic lateral sclerosis (Keren-Shaul et al., 2017; Zhou et al., 2020; Krasemann et al., 2017; Sala Frigerio et al., 2019; Hammond et al., 2019; Mathys et al., 2017; Friedman et al., 2018; Wang et al., 2020; Ellwanger et al., 2021; Li et al., 2019).”
BackgroundSoluble TREM2 triggers microglial dysfunction in neuromyelitis optica spectrum disorders
Qin, C., Chen, M., Dong, M., Yang, S., Zhang, H., You, Y., Zhou, L., Chu, Y., Tang, Y., Pang, X., et al. (2023) · Brain · doi:10.1093/brain/awad321 · Cited by 58
LILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00550-y · Cited by 54
“CD68, the phagocytic marker of microglia, is frequently used to study the phagocytic status of plaque proximal microglia [35, 54, 55].”
BackgroundMethodPocock, J., Vasilopoulou, F., Svensson, E., & Cosker, K. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110020 · Cited by 54
Central Nervous System Macrophages in Health and Disease
Hove, H. V., Feo, D. D., Greter, M., & Becher, B. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041334 · Cited by 53
Ma, Y., Hu, X., Karako, K., Song, P., Tang, W., & Xia, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1576020 · Cited by 55
Claes, C., England, W. E., Danhash, E. P., Kiani Shabestari, S., Jairaman, A., Chadarevian, J. P., Hasselmann, J., Tsai, A. P., Coburn, M. A., Sanchez, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12577 · Cited by 62
Wang, Q., Lu, M., Zhu, X., Gu, X., Zhang, T., Xia, C., Yang, L., Xu, Y., & Zhou, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113412 · Cited by 52
Li, C., Ren, J., Zhang, M., Wang, H., Fang, Y., Wu, J., & Tang, Y. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04536-3 · Cited by 57
The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial
Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., 高晶晶, Budda, B., Park, L. Q., Gupta, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04273-1 · Cited by 60
Self-citationSystemic inflammation as a central player in the initiation and development of Alzheimer’s disease
Bayraktaroğlu, I., Ortí-Casañ, N., Dam, D. V., Deyn, P. P. D., & Eisel, U. L. M. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00529-5 · Cited by 54
New insight on microglia activation in neurodegenerative diseases and therapeutics
Xu, Y., Gao, W., Sun, Y., & Wu, M. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1308345 · Cited by 54
Reich, M., Paris, I., Ebeling, M., Dahm, N., Schweitzer, C., Reinhardt, D., Schmucki, R., Prasad, M., Köchl, F., Leist, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.617860 · Cited by 49
Gao, C., Shen, X., Tan, Y., & Chen, S. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02580-1 · Cited by 52
Microglia-Mediated Neurovascular Unit Dysfunction in Alzheimer’s Disease
Huang, W., Xia, Q., Zheng, F., Zhao, X. L., Ge, F., Xiao, J., Liu, Z., Shen, Y., Ye, K., Wang, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221064 · Cited by 51
Singh, H., Rai, V., Nooti, S. K., & Agrawal, D. K. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1883587 · Cited by 47
Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 51
TREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain
Fruhwürth, S., Reinert, L. S., Öberg, C., Sakr, M., Henricsson, M., Zetterberg, H., & Paludan, S. R. (2023) · Science Advances · doi:10.1126/sciadv.adf5808 · Cited by 40
Roles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 50
The impact of rare genetic variants on Alzheimer disease
Deyn, L. D., & Sleegers, K. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01062-1 · Cited by 50
Hou, J., Chen, Y., Cai, Z., Heo, G. S., Yuede, C. M., Wang, Z., Lin, K., Saadi, F., Tršan, T., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9052 · Cited by 45
Self-citationTondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
Sethi, P., Bhaskar, R., Singh, K. K., Gupta, S., Han, S. S., Avinash, D., Abomughaid, M. M., Koul, A., Rani, B., Ghosh, S., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102411 · Cited by 52
Immune modulation to treat Alzheimer’s disease
Duggan, M. R., Morgan, D., Price, B. R., Rajbanshi, B., Martín‐Peña, A., Tansey, M. G., & Walker, K. A. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00828-x · Cited by 49
Innate Immunity and Cell Death in Alzheimer’s Disease
Lee, S., Cho, H.-J., & Ryu, J.-H. (2021) · ASN Neuro · doi:10.1177/17590914211051908 · Cited by 45
Immune dysfunction in Alzheimer disease
Butovsky, O., Rosenzweig, N., Kleemann, K. L., Jorfi, M., Kuchroo, V. K., Tanzi, R. E., & Weiner, H. L. (2025) · Nature reviews. Neuroscience · doi:10.1038/s41583-025-00997-0 · Cited by 48
APOE and immunity: Research highlights
Kloske, C. M., Barnum, C. J., Batista, A. F., Bradshaw, E. M., Brickman, A. M., Bu, G., Dennison, J. L., Gearon, M. D., Goate, A., Haass, C., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13020 · Cited by 46
Chen, P., Chen, F., Lei, J., & Zhou, B. (2023) · Phytotherapy Research · doi:10.1002/ptr.7848 · Cited by 42
Modulating Neuroinflammation as a Prospective Therapeutic Target in Alzheimer’s Disease
Lee, E., & Chang, Y. (2025) · Cells · doi:10.3390/cells14030168 · Cited by 47
Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer’s disease
Abellanas, M. A., Purnapatre, M., Burgaletto, C., & Schwartz, M. (2025) · Nature Neuroscience · doi:10.1038/s41593-024-01847-5 · Cited by 42
McKee, C., Hoffos, M., Vecchiarelli, H. A., & Tremblay, M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1125982 · Cited by 40
Winfree, R. L., Seto, M., Dumitrescu, L., Menon, V., De Jager, P., Wang, Y., Schneider, J., Bennett, D. A., Jefferson, A. L., & Hohman, T. J. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02564-2 · Cited by 40
TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages
Chen, X., Zhao, Y., Huang, Y., Zhu, K., Zeng, F., Zhao, J., Zhang, H., Zhu, X., Kettenmann, H., & Xiang, X. (2023) · Glia · doi:10.1002/glia.24456 · Cited by 40
Zhou, Y., Xu, J., Hou, Y., Bekris, L., Leverenz, J. B., Pieper, A. A., Cummings, J., & Cheng, F. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12350 · Cited by 39
Feiten, A. F., Dahm, K., Schlepckow, K., van Lengerich, B., Suh, J. H., Reifschneider, A., Wefers, B., Bartos, L. M., Wind-Mark, K., de Weerd, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68706-8 · Cited by 39
“Variants of TREM2 are associated with increased risk for late-onset AD, and the paper aims to better understand the molecular and functional changes that occur in microglia when TREM2 is either upregulated or downregulated.”
Does soluble TREM2 protect against Alzheimer's disease?
Brown, G. C., & St George-Hyslop, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.834697 · Cited by 39
Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases
Liu, J., Ting, J. P., Al-Azzam, S., Ding, Y., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062805 · Cited by 40
Roles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 42
Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation
Kumar, D., Ashraf, G. M., Bilgrami, A. L., & Hassan, M. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.06.005 · Cited by 42
Gao, H., Di, J., Clausen, B. H., Wang, N., Zhu, X., Zhao, T., Chang, Y., Pang, M., Yang, Y., He, R., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112629 · Cited by 38
Zhang, C., Qi, H., Jia, D., Zhao, J., Xu, C., Liu, J., Cui, Y., Zhang, J., Wang, M., Chen, M., et al. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122457 · Cited by 40
Eskandari‐Sedighi, G., Crichton, M. C., Zia, S., Gomez‐Cardona, E., Cortez, L. M., Patel, Z. H., Takahashi, K., Laurent, C. D. S., Sidhu, G., Sarkar, S., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00734-8 · Cited by 38
Shen, Y., Liu, F., & Zhang, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117235 · Cited by 41
Microglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease
Qu, W., & Li, L. (2021) · The Neuroscientist · doi:10.1177/10738584211040786 · Cited by 40
Matuszyk, M. M., Garwood, C. J., Ferraiuolo, L., Simpson, J. E., Staniforth, R. A., & Wharton, S. B. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15538 · Cited by 38
Targeting TREM2 for Parkinson’s Disease: Where to Go?
Li, X.-X., & Zhang, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.795036 · Cited by 36
INPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model
Iguchi, A., Takatori, S., Kimura, S., Muneto, H., Wang, K., Etani, H., Ito, G., Sato, H., Hori, Y., Sasaki, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106375 · Cited by 42
Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques
Natunen, T., Martiskainen, H., Marttinen, M., Gabbouj, S., Koivisto, H., Kemppainen, S., Kaipainen, S., Takalo, M., Svobodová, H., Leppänen, L., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00415-2 · Cited by 35
Dysfunctional microglia and tau pathology in Alzheimer’s disease
Ayyubova, G. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0087 · Cited by 35
The emerging role of brain neuroinflammatory responses in Alzheimer’s disease
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1391517 · Cited by 40
Microglial TREM2 in amyotrophic lateral sclerosis
Xie, M., Zhao, S., Bosco, D. B., Nguyen, A. T., & Wu, L. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22864 · Cited by 36
Althafar, Z. M. (2022) · Molecules · doi:10.3390/molecules27134124 · Cited by 35
Luo, Q., Schnöder, L., Hao, W., Litzenburger, K., Decker, Y., Tomic, I., Menger, M. D., Fassbender, K. C., & Liu, Y. (2022) · Aging Cell · doi:10.1111/acel.13679 · Cited by 36
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
Yang, S., Yang, Y., Wang, F., Luo, Q., Zhang, Y., Zheng, F., Shu, Q., Chen, Q., & Fang, X. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0521oc · Cited by 36
Reduced TREM2 activation in microglia of patients with Alzheimer's disease
Okuzono, Y., Sakuma, H., Miyakawa, S., Ifuku, M., Lee, J. H., Das, D., Banerjee, A., Zhao, Y., Yamamoto, K., Ando, T., et al. (2021) · FEBS Open Bio · doi:10.1002/2211-5463.13300 · Cited by 40
Etxeberria, A., Shen, Y.-A. A., Vito, S., Silverman, S. M., Imperio, J., Lalehzadeh, G., Soung, A. L., Du, C., Xie, L., Choy, M. K., et al. (2024) · The Journal of Neuroscience · doi:10.1523/jneurosci.2347-23.2024 · Cited by 35
Disease-modifying therapies for Alzheimer’s disease: Clinical trial progress and opportunity
Zhang, Y., Chen, J., Li, Y., Jiao, B., & Luo, S. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102595 · Cited by 38
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 35
TREM2 and Microglia Contribute to the Synaptic Plasticity: from Physiology to Pathology
Yu, C.-J., Wang, M., Ruiyang, L., Wei, T., Yang, H.-C., Yin, Y., Mi, Y., Qin, Q., & Tang, Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03100-1 · Cited by 36
Pang, X., Chu, Y., Zhou, L., Chen, M., You, Y., Tang, Y., Yang, S., Zhang, H., Xiao, J., Deng, G., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15987 · Cited by 36
TREM2+ macrophages: a key role in disease development
Wang, X., Wang, Y., Yang, L. X., Zhang, Y., & Yang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1550893 · Cited by 44
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 38
Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases
Rickenbach, C., & Gericke, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.806260 · Cited by 37
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 37
Interplay between microglia and environmental risk factors in Alzheimer's disease
Zhang, M., Liang, C., Chen, X., Cai, Y., & Cui, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.389745 · Cited by 32
Yan, H., Wang, W., Cui, T., Shao, Y., Li, M., Fang, L., & Feng, L. (2024) · ImmunoTargets and Therapy · doi:10.2147/itt.s455881 · Cited by 33
Myelin debris phagocytosis in demyelinating disease
Gao, R., Song, S., Tian, M., Wang, L., Zhang, Y., & Li, X. (2024) · Glia · doi:10.1002/glia.24602 · Cited by 35
Ghimire, A., Rehman, S. A., Subhani, A., Khan, M. A., Rahman, Z., Iqubal, M. K., & Iqubal, A. (2025) · hLife · doi:10.1016/j.hlife.2024.11.006 · Cited by 38
Chen, K., Li, F., Zhang, S., Chen, Y., Ikezu, T. C., Li, Z., Martens, Y. A., Qiao, W., Meneses, A. D., Zhu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03420-8 · Cited by 35
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The journal of prevention of Alzheimer's disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 30
Biological correlates of elevated soluble TREM2 in cerebrospinal fluid
Winfree, R. L., Dumitrescu, L., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Jefferson, A. L., & Hohman, T. J. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.013 · Cited by 31
Chen, J., Zhao, S., Zhou, Y., Wang, L., Chen, Q., & Zheng, K. (2025) · BioScience Trends · doi:10.5582/bst.2025.01148 · Cited by 34
Lipid droplets in the nervous system: involvement in cell metabolic homeostasis
Zhang, Y., Chen, Y., Zhuang, C., Qi, J., Zhao, R. C., & Wang, J. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01401 · Cited by 31
The double-edged role and therapeutic potential of TREM2 in atherosclerosis
Zhu, B., Liu, Y., & Peng, D. (2024) · Biomarker Research · doi:10.1186/s40364-024-00675-w · Cited by 32
Hassan, H., Rawlinson, C., Lan, Y., Jenkins, S. I., & Chen, R. (2025) · Biomolecules · doi:10.3390/biom15111629 · Cited by 34
A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation
Ralvenius, W. T., Mungenast, A. E., Woolf, H., Huston, M. M., Gillingham, T. Z., Godin, S. K., Penney, J., Cam, H. P., Gao, F., Fernandez, C. G., et al. (2023) · Journal of Experimental Medicine · doi:10.1084/jem.20222105 · Cited by 29
TREM2 in Alzheimer's disease: Structure, function, therapeutic prospects, and activation challenges
Zgórzyńska, E. (2024) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2024.103917 · Cited by 30
Aging and cognitive resilience: Molecular mechanisms as new potential therapeutic targets
Cordeiro, A., Gomes, C., Bicker, J., & Fortuna, A. C. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104093 · Cited by 31
Takatori, S., Kondo, M., & Tomita, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00383-4 · Cited by 29
Trem2 H157Y increases soluble TREM2 production and reduces amyloid pathology
Qiao, W., Chen, Y., Zhong, J., Madden, B. J., Charlesworth, C. M., Martens, Y. A., Liu, C., Knight, J. A., Ikezu, T. C., Kurti, A., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00599-3 · Cited by 31
Vautheny, A., Duwat, C., Aurégan, G., Joséphine, C., Hérard, A.-S., Jan, C., Mitja, J., Gipchtein, P., Gaillard, M.-C., Buée, L., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105398 · Cited by 28
New Insights into Molecular Mechanisms Underlying Neurodegenerative Disorders
Liu, J., Duan, W., Deng, Y., Zhang, Q., Li, R., Long, J., Waqas, A., Gu, C., Qiu, Y., Cai, H., et al. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2203058 · Cited by 28
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
Knowledge gaps in Alzheimer's disease immune biomarker research
Morgan, D., & Mielke, M. M. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12342 · Cited by 27
Lin, C., Kong, Y., Chen, Q., Zeng, J., Pan, X., & Miao, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1420731 · Cited by 27
Brain resident microglia in Alzheimer’s disease: foe or friends
Kaur, S., Malleshwari, K., Sharma, A., Giridharan, V. V., & Dandekar, M. P. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01550-8 · Cited by 27
Metadata
- Authors
- Wang, S., Mustafa, M., Yuede, C. M., Salazar, S. V., Kong, P., Long, H., Ward, M., Siddiqui, O., Paul, R., Gilfillan, S., Ibrahim, A., Rhinn, H., Tassi, I., Rosenthal, A., Schwabe, T., & Colonna, M.
- Affiliations
- Washington University in St. Louis (US)
- Alector (United States) (US)
- Corresponding author
- Schwabe, Tina
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2020-06-24
- Volume
- 217
- Issue
- 9
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC7478730
- OpenAlex
- W3037497912
- Cited by
- 549
- References
- 41
- Citations by year
- 2026: 106 · 2025: 115 · 2024: 101 · 2023: 93 · 2022: 64 · 2021: 52 · 2020: 18
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (RF1AG05148501, R21 AG059176, RF1 AG059082)
- Cure Alzheimer’s Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- TREM2, Alzheimer's disease, microglial proliferation, amyloid plaques, microglial inflammation, transgenic mouse model, single-cell RNA sequencing, cerebrospinal fluid biomarkers, immunotherapy
- MeSH terms
- Alzheimer Disease, Animals, Antibodies, Monoclonal, Anxiety, Blood-Brain Barrier, Disease Models, Animal, Humans, Membrane Glycoproteins, Mice, Inbred C57BL, Mice, Transgenic, Protein Conformation, Receptors, Immunologic, Solubility, Signal Transduction, Biomarkers, Amyloid beta-Peptides, Neurites, Microglia, Cell Proliferation, Osteopontin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.